Myeloid cells' contribution is key in CRS pathophysiology induced by T-cell engagers in BRGSF-HIS model

T-cell engagers show high efficacy in B-cell malignancies. A high risk of immune-related adverse events, including cytokine release syndrome (CRS), is reported in patients treated with T-cell engagers due to on-target offsite effects. Thus, reliable and translational mouse models are required to predict potential safety issues and investigate their rescue. PBMC-reconstituted models are the most currently used as preclinical models to investigate CRS induction’ while CD34⁺ reconstituted ones are more rarely described for this application.